Ribometrix Takes Aim at “Undruggable” RNA with $30M Series A Funding
Summary
That’s changing though—just in the last couple of years, there’s been a mini-boom in biotechs trying to overturn the long-held dogma that messenger RNA molecules (which carry the genetic instructions for proteins to the cell’s protein-making machinery) are undruggable.The latest startup on this quest is Ribometrix out of Durham, NC, which today announced a $30 million Series A round of financing to fund the development of small molecule drugs targeting RNA involved in cancer and neurodegeneration.To determine RNA structures, the company has taken technology from the research group of Kevin Weeks of University of North Carolina at Chapel Hill (UNC), and built it out into a drug development platform.A research version of the SHAPE technology, which originated from Weeks’s lab at UNC, is publicly available and widely used by scientists in the RNA field, including those from competing drug companies.Arrakis has also expanded the SHAPE technology and built its own bioinformatics software and other tools around it for drug discovery, says Jennifer Petter, Arrakis’s founder and chief scientific officer.
Funding
Review available funding amount, funding date, investors, and linked company information related to Ribometrix Takes Aim at “Undruggable” RNA with $30M Series A Funding in the interactive ISVWorld profile.
Classifications
AskAI Classifications
LabelsLinked Companies
